Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP430822.RA6NnPT1v6WY4P8l9aginjN-Tir2eOxBynUGZsXx0qV3c130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP430822.RA6NnPT1v6WY4P8l9aginjN-Tir2eOxBynUGZsXx0qV3c130_assertion type Assertion NP430822.RA6NnPT1v6WY4P8l9aginjN-Tir2eOxBynUGZsXx0qV3c130_head.
- NP430822.RA6NnPT1v6WY4P8l9aginjN-Tir2eOxBynUGZsXx0qV3c130_assertion description "[We have observed that molecular response, as defined by a PCR-negative status during the first year of therapy, along with beta 2-microglobulin (beta 2M), was the most important variable associated with failure-free survival (FFS) in follicular lymphoma (FL).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP430822.RA6NnPT1v6WY4P8l9aginjN-Tir2eOxBynUGZsXx0qV3c130_provenance.
- NP430822.RA6NnPT1v6WY4P8l9aginjN-Tir2eOxBynUGZsXx0qV3c130_assertion evidence source_evidence_literature NP430822.RA6NnPT1v6WY4P8l9aginjN-Tir2eOxBynUGZsXx0qV3c130_provenance.
- NP430822.RA6NnPT1v6WY4P8l9aginjN-Tir2eOxBynUGZsXx0qV3c130_assertion SIO_000772 10707796 NP430822.RA6NnPT1v6WY4P8l9aginjN-Tir2eOxBynUGZsXx0qV3c130_provenance.
- NP430822.RA6NnPT1v6WY4P8l9aginjN-Tir2eOxBynUGZsXx0qV3c130_assertion wasDerivedFrom befree-20140225 NP430822.RA6NnPT1v6WY4P8l9aginjN-Tir2eOxBynUGZsXx0qV3c130_provenance.
- NP430822.RA6NnPT1v6WY4P8l9aginjN-Tir2eOxBynUGZsXx0qV3c130_assertion wasGeneratedBy ECO_0000203 NP430822.RA6NnPT1v6WY4P8l9aginjN-Tir2eOxBynUGZsXx0qV3c130_provenance.